Abstract
Cytogenetic abnormalities are used to define prognostic subgroups of acute myelogenous leukemia (AML) with respect to achieving complete remission (CR) and remaining disease free. These prognostic groups for obtaining CR were based on an induction regimen mainly using standard dose cytosine arabinoside (Ara-C) + daunorubicin (DNR). We have reviewed our experience with 122 adult patients with de novo non-M3 AML who were treated with high-dose (HD) Ara-C 3 g/m2 given over 3 h every 12 h for a total of eight doses followed by DNR 60 mg/m2 daily for 2 days. CR was obtained in 80% while 16% had refractory disease and 4% died of sepsis during hypoplasia. CR rate for favorable, intermediate and unfavorable cytogenetic groups were 87%, 79% and 62%, respectively (P = 0.32). High white blood cell count, age, FAB subtype and LDH levels did not adversely affect CR rate. Eighty-five percent of patients achieved CR with one course of treatment and 87% of complete responders were able to receive post remission therapy. High-dose Ara-C/DNR appears to offer an excellent chance of achieving remission for patients with AML including those with poor risk cytogenetics, without an increase in early toxic deaths.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Yates J, Glidewell O, Wiernik P, Cooper RM, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF . Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study Blood 1982 60: 454–462
Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, Preisler HD, Nawabi IW, Prager D, Carey RW, Cooper RM, Haurani F, Hutchison JL, Silver RT, Falkson G, Wiernik P, Hoagland HC, Bloomfield CD, James GW, Gottlieb A, Ramanen SV, Bloom J, Nissen NI, Bank A, Ellison RR, Kung F, Henry P, McIntyre OR, Kaan SK . Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B Blood 1981 58: 1203–1212
Preisler H, Davis RB, Kirshner J, Dupre E, Richards F, Hoagland HC, Kopel S, Levy RN, Carey R, Schulman P, Gottlieb AJ, McIntyre RO . Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study Blood 1987 69: 1441–1449
Gale RP, Foon FA, Cline MJ, Zighelboim J, UCLA Acute Leukemia Study Group . Intensive chemotherapy for acute myelogenous leukemia Ann Intern Med 1981 94: 753–757
Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwar S, Young C, Clarkson B . Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia Blood 1991 77: 1666–1674
Vogler WR, Velez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PLC . A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study J Clin Oncol 1992 10: 1103–1111
Wiernik PH, Banks PLC, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB . Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood 1992 79: 313–319
Van Prooijen HC, Dekker AW, Punt K . The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse Br J Haematol 1984 57: 291–299
Capizzi RL, Poole M, Cooper MR, Richards F, Stuart JJ, Jackson DV, White DR, Spurr CL, Hopkins JO, Muss HB, Rudnick SA, Wells R, Gabriel D, Ross D . Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase Blood 1984 63: 694–770
Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Büchner T . High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia Blood 1987 69: 744–749
Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP . High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia J Clin Oncol 1985 3: 992–997
Browman G, Preisler H, Raza A, Syracuse K, Azarnia N, Benger A, Chervenick P, D'Arrigo P, Doeblin T, Goldberg J, Gottlieb A, Grunwald H, Kirshner J, Larson B, Meyer R, Miller K, Priore R, Stein M, Vogler WR, Walker I, Wilson WEC, Barcos M . Use of the day 6 bone marrow to the alter remission induction therapy in patients with acute myeloid leukaemia: a Leukemia Intergroup Study Br J Haematol 1989 71: 493–497
Bolwell BJ, Cassileth A, Gale RP . High-dose cytarabine: a review Leukemia 1988 2: 253–260
Hiddemann W . Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens Ann Hematol 1991 62: 119–128
Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP . High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia J Clin Oncol 1985 3: 992–997
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E and the Cancer and Leukemia Group B . Intensive postremission chemotherapy in adults with acute myeloid leukemia New Engl J Med 1994 331: 896–903
Forman SJ, Nademanee AP, O'Donnell MR, Fahey JL, Snyder DS, Farbstein MJ, Lazard GS, DuBois NJ, Blume KG . High-dose cytosine arabinoside and daunomycin as primary therapy for adults with acute nonlymphocytic leukemia: a pilot study Semin Oncol 1985 12: 114–116
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A . The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial Blood 1998 92: 2322–2333
Alsabeh R, Brynes R, Slovak ML, Arber DA . Acute myeloid leukemia with t(6;9)(p23;q34) association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype Am J Clin Pathol 1997 107: 430–437
Von Lindern M, Fornerod M, Soekarman N, Van Baal S, Jaegle M, Hagemeijer A, Bootsma D, Grosveld G . Translocation t(6;9) in acute non-lymphocytic leukemia results in the formation of a DEK-CAN fusion gene Baillières Clin Haematol 1992 5: 857–879
Soekarman D, Von Lindern M, Daenen S, De Jong B, Fonatsch C, Heinze B, Bartram C, Hagemeijer A, Grosveld G . The translocation (6;9)(p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features Blood 1992 79: 2990–2997
Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky A, Stass S, Weinstein H, Woods WG . Report of the National Cancer Institute-Sponsored Workshop on Definitions of Diagnosis and Response in Acute Myeloid Leukemia J Clin Oncol 1990 8: 813–819
Hosmer DW, Lemeshow S . Applied Logistic Regression John Wiley: New York 1989
LogXact for Windows Cytel Software: Cambridge, MA 1996
Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson MO, Juneja S . A randomized study of high-dose cytarabine in induction in a acute myeloid leukemia Blood 1996 87: 1710–1717
Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M . A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study Blood 1996 88: 2841–2851
Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L, Broccia G, Thaler J, Labar B, Damasio E, Bizzi B, Rotoli B, Vekhoff A, Muus P, Petti MC, Dardenne M, Solbu G, Vegna ML, Zittoun RA . Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remisson: an analysis of the EORTC-GIMEMA AML 8A trial Bone Marrow Transplant 1996 17: 993–1001
Fourth International Workshop on Chromosomes in Leukemia 1982 . Clinical significance of chromosomal abnormalities in acute nonlymphoblastic leukemia Cancer Genet Cytogenet 1984 11: 332–350
Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ . Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype Cancer Res 1998 58: 4173–4179
Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil K, Mohamed A, Chung A, Paietta E, Willman C, Head DR, Forman SJ, Appelbaum FR . Karyotypic analysis predicts outcome of pre- and post-remission therapy in adult acute myeloid leukemia (AML): a SWOG/ECOG intergroup study Blood 1998 92: 678a (Abstr. 2795)
Hann IM, Stevens RF, Goldstone AH, Rees JKH, Wheatley K, Gray RG, Burnett AKL . Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10) Blood 1997 89: 2311–2318
Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, Sauerland MC, Heinecke A . Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group Blood 1999 93: 4116–4124
Bishop JF, Matthews JP, Young G, Bradstock K, Lowenthall RM . Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group Leuk Lymphoma 1998 28: 315–327
Lowenthal RM, Bradstock KF, Matthews LP, Bishop JF, Juneja S, Cobcroft R, Eliadis P, Enno A, Gill D, Herrmann RP, Manoharan A, Page FJ, Rooney KF, Rosenfeld D, Seldon M, Taylor KM, Wolf MM, Young G . A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia Leuk Lymphoma 1999 34: 501–510
Acknowledgements
This work was supported in part by grants CA 30206 and CA 33572 from the National Cancer Institute, Department of Health and Human Services (DHHS NIH, Bethesda, MD). We are grateful to Diana Garcia for assistance in the preparation of the manuscript. We would also like to thank Annette Brown and Trudy Trimmer for their assistance in data collection.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stein, A., O'Donnell, M., Slovak, M. et al. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia 14, 1191–1196 (2000). https://doi.org/10.1038/sj.leu.2401839
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401839